Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H10N2O2 |
Molecular Weight | 226.2307 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=CC2=C(NC3=CC=CC=C23)C=N1
InChI
InChIKey=UKHFPVCOXBJPIN-UHFFFAOYSA-N
InChI=1S/C13H10N2O2/c1-17-13(16)11-6-9-8-4-2-3-5-10(8)15-12(9)7-14-11/h2-7,15H,1H3
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6300400 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands. | 2000 Jul |
|
Mice lacking the long splice variant of the gamma 2 subunit of the GABA(A) receptor are more sensitive to benzodiazepines. | 2000 Jun |
|
Identification of amino acid residues responsible for the alpha5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABA(A) receptor. | 2001 Apr |
|
Effects of diazepam and beta-CCM on working memory in mice: relationships with emotional reactivity. | 2001 Feb |
|
The octadecaneuropeptide ODN stimulates neurosteroid biosynthesis through activation of central-type benzodiazepine receptors. | 2001 Jan |
|
Form II of monoclinic methyl beta-carboline-3-carboxylate. | 2001 Jun |
|
[3H]Ro 15-1788 binding sites to brain membrane of the saltwater Mugil cephalus. | 2001 Mar |
|
Modification of the effects of benzodiazepines on the exploratory behaviors of mice on a hole-board by diabetes. | 2001 May |
|
The negative GABA(A) modulator methyl beta-carboline-3-carboxylate attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone in rhesus monkeys. | 2001 Nov |
|
A pharmacological link between epilepsy and anxiety? | 2001 Oct |
|
The effects of flumazenil, Ro 154513 and beta-CCM on the behaviour of control and stressed mice in the staircase test. | 2001 Sep |
|
Daily treatment with diazepam differentially modifies sensitivity to the effects of gamma-aminobutyric acid(A) modulators on schedule-controlled responding in rhesus monkeys. | 2002 Mar |
|
Mouse lines differing in sensitivity to beta-CCM differ in tasks used for testing antidepressants. | 2002 May |
|
Long-lasting potentiation effects induced in rats by kindling with an inverse agonist of the benzodiazepine receptor. | 2002 Sep |
|
Photophysical properties of methyl beta-carboline-3-carboxylate mediated by hydrogen-bonded complexes--a comparative study in different solvents. | 2003 Jul 1 |
|
BetaCCM enhances retrieval of serial contextual but not of serial spatial memory in mice. | 2004 Mar |
|
BetaCCM but not physostigmine enhancement of memory retrieval depends on emotional processes in mice. | 2004 Oct |
|
Abnormal benzodiazepine receptor function in the depressive-like behavior of diabetic mice. | 2005 Dec |
|
Effects of ibotenic acid lesions of the mediodorsal thalamus on memory: relationship with emotional processes in mice. | 2005 Jan 30 |
|
Negative GABA(A) modulators attenuate the discriminative stimulus effects of benzodiazepines and the neuroactive steroid pregnanolone in rhesus monkeys. | 2005 Oct |
|
Mouse lines selected for difference in sensitivity to beta-CCM also differ in memory processes. | 2006 Oct 16 |
|
Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG). | 2006 Sep 19 |
|
Chemoconvulsant-induced seizure susceptibility: toward a common genetic basis? | 2007 |
|
Effects of toluene exposure during brain growth spurt on GABA(A) receptor-mediated functions in juvenile rats. | 2007 Feb |
|
Inverse benzodiazepine agonist beta-CCM does not reverse learning deficit induced by sleep deprivation. | 2010 Jan 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19962429
Male Wistar rats: were treated with saline or 0.5mg/kg beta-CCM (Methyl β-carboline-3-carboxylat) before passive avoidance training (AD), and were tested 30 min or 24h later. beta-CCM increased passive avoidance (PA) performance in control animals in both short and long term retention tests, whereas SD and SR animals were unaffected by the drug treatment.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C036150
Created by
admin on Sat Dec 16 18:10:33 GMT 2023 , Edited by admin on Sat Dec 16 18:10:33 GMT 2023
|
PRIMARY | |||
|
107704
Created by
admin on Sat Dec 16 18:10:33 GMT 2023 , Edited by admin on Sat Dec 16 18:10:33 GMT 2023
|
PRIMARY | |||
|
69954-48-9
Created by
admin on Sat Dec 16 18:10:33 GMT 2023 , Edited by admin on Sat Dec 16 18:10:33 GMT 2023
|
PRIMARY | |||
|
DTXSID40990214
Created by
admin on Sat Dec 16 18:10:33 GMT 2023 , Edited by admin on Sat Dec 16 18:10:33 GMT 2023
|
PRIMARY | |||
|
I2A008F6YL
Created by
admin on Sat Dec 16 18:10:33 GMT 2023 , Edited by admin on Sat Dec 16 18:10:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD